Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference

. 2015 Dec;3(Suppl):S1-4.

doi: 10.1016/j.prnil.2015.10.014. Epub 2015 Oct 22.

Affiliations

¹ ICON Cancer Care, Brisbane, Queensland, Australia; Centre for Personalized Nanomedicine, University of Queensland, Australia.
² Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies, Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Japan.

Paul Mainwaring et al. Prostate Int. 2015 Dec.

. 2015 Dec;3(Suppl):S1-4.

doi: 10.1016/j.prnil.2015.10.014. Epub 2015 Oct 22.

¹ ICON Cancer Care, Brisbane, Queensland, Australia; Centre for Personalized Nanomedicine, University of Queensland, Australia.
² Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies, Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Japan.

No abstract available

References

1. Chaturvedi S., Garcia J.A. Novel agents in the management of castration resistant prostate cancer. J Carcinog. 2014;13:5. - PMC - PubMed
1. Saad F., Fizazi K.S. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-Sensitive and Castration Resistant Prostate Cancer. Urology. 2015 pii: S0090–4295(15)00729-3. [Epub ahead of print] - PubMed
1. Loblaw D.A., Walker-Dilks C., Winquist E., Hotte S.J. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol. (R. Coll. Radiol.) 2013;25:406–430. - PubMed
1. Yap T.A., Zivi A., Omlin A., de Bono J.S. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8:597–610. - PubMed
1. Crawford E.D., Higano C.S., Shore N.D., Hussain M., Petrylak D.P. Treating patients with metastatic castration-resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015 pii: S0022–5347(15)04423-7. [Epub ahead of print] - PubMed